Belviq: the New FDA Approved Obesity-Fighting Drug

REPLAY VIDEO
Your next video will start in
Pause

Recommended Videos

  • Info

  • Comments

  • VIDEO TEXT

Jan.14 (Bloomberg) –- Arena Pharmaceuticals President & CEO Jack Lief and Eisai President & CEO Lonnel Coats discuss the new obesity-fighting drug, Belviq, how it works and the potential side effects with Mark Crumpton on Bloomberg Television's "Taking Stock." (Source: Bloomberg)

It works in the brain to reduce appetite.

Patients who want to diet and find they have an insatiable hunger to pick up a piece of pie or go off their diet, this addresses their appetite and reduces it.

Patients are very successful at losing weight.

We are thrilled to be able to bring this first in class new chemical entity, the first when the fda has approved for the medical management of obesity since 1999. i wanted to talk about that.

That is a long time.

Why do you suppose it has taken so long?

It is a difficult time to address.

Humans -- difficult area to address.

Humans are genetically programmed to gain weight.

A lot of people need extra help reducing their weight, and this drug provides that extra tool for physicians and patients to be able to achieve their goals.

Mr.

coates, let's talk about the potential side effects.

What are they?

Generally speaking, with a product like this, dry mouth and headache are the most common side effects.

Let me talk to you about the effectiveness in terms of what patients would expect in taking it.

Patients who would take it once, at 10 milligram tablet twice a day, can expect to lose a up to five percent of their body weight within 12 weeks.

We save they do not reach those numbers, they should go back to their physician.

The majority of patients will hit those targets.

If they stay on, they will go on to lose additional bodyweight and the majority of those will keep that weight off for more than a year.

Is this in combination with strict dietary exercise?

Absolutely.

The most responsible thing we can say is it is always important that patients have good nutrition and exercise and have good activity combined with therapy like this.

Then they have the greatest chance of achieving their overall goals.

We have to talk about costs.

This is expensive.

The numbers i saw online today but the cost upwards of $250. are you expanding reimbursement coverage?

That is eisai's responsibility, but as he said, they've have expanded the recovering point nicely from 30%. this year they expect to be at 50% reimbursed.

That is major progress being done there.

Mr.

coatess, how to improve the dialogue between patients and their doctors about the myriad risks of obesity?

Rex that is a great -- that is a great question.

We did some work with the obesity coalition and the obesity society.

What we found, remarkably, is that the dialogue between patients and physicians is misunderstood.

Physicians believe they are making complete discussions with patients.

Patients report they are not getting the information they need.

We have started a program called let's have a healthy discussion, so that we can revive physicians with the tools that help them be able to explain body mass index and what does that mean to their overall health, and also, how do we engage consumers to ask the right questions of physicians.

We are playing a responsible role to make sure that dialogue takes place and then we can survey begin to make steady progress and a laminating this issue in the united states.

Iq to -- in eliminating this

This text has been automatically generated. It may not be 100% accurate.

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change